Abstract: The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), aggrecanase, or a combination thereof.
Type:
Grant
Filed:
May 23, 2002
Date of Patent:
May 10, 2005
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman